Weekly Analysts’ Ratings Changes for Pharmerica Corporation (PMC)

A number of firms have modified their ratings and price targets on shares of Pharmerica Corporation (NYSE: PMC) recently:

  • 10/4/2017 – Pharmerica Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation. As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues. “
  • 9/27/2017 – Pharmerica Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $33.00 price target on the stock. According to Zacks, “PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation. As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues. “
  • 9/26/2017 – Pharmerica Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation. As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues. “
  • 9/22/2017 – Pharmerica Corporation was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.

Pharmerica Corporation (NYSE:PMC) last announced its earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.47. The business had revenue of $592.00 million for the quarter, compared to the consensus estimate of $592.96 million. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. Pharmerica Corporation’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period last year, the firm posted $0.47 earnings per share.

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply